These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme. Saxena V; Hussain MD Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704 [TBL] [Abstract][Full Text] [Related]
4. Targeting breast cancer using pirarubicin-loaded vasoactive intestinal peptide grafted sterically stabilized micelles. Eskandari Z; Bahadori F; Yapaoz MA; Yenigun VB; Celikten M; Kocyigit A; Onyuksel H Eur J Pharm Sci; 2021 Jul; 162():105830. PubMed ID: 33819623 [TBL] [Abstract][Full Text] [Related]
5. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Rubinstein I; Soos I; Onyuksel H Chem Biol Interact; 2008 Jan; 171(2):190-4. PubMed ID: 17499651 [TBL] [Abstract][Full Text] [Related]
6. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG. Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994 [TBL] [Abstract][Full Text] [Related]
7. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment. Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932 [TBL] [Abstract][Full Text] [Related]
8. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer. Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799 [TBL] [Abstract][Full Text] [Related]
9. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204 [TBL] [Abstract][Full Text] [Related]
10. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells. Roforth MM; Tan C Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209 [TBL] [Abstract][Full Text] [Related]
11. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Onyüksel H; Jeon E; Rubinstein I Cancer Lett; 2009 Feb; 274(2):327-30. PubMed ID: 19022562 [TBL] [Abstract][Full Text] [Related]
12. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Koo OM; Rubinstein I; Onyuksel H Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061 [TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model. Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284 [TBL] [Abstract][Full Text] [Related]
14. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells. Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586 [TBL] [Abstract][Full Text] [Related]
15. Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy. Shin DH; Kwon GS Int J Pharm; 2017 Feb; 518(1-2):307-311. PubMed ID: 28062368 [TBL] [Abstract][Full Text] [Related]
16. Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells. Gülçür E; Thaqi M; Khaja F; Kuzmis A; Önyüksel H Drug Deliv Transl Res; 2013 Dec; 3(6):. PubMed ID: 24363979 [TBL] [Abstract][Full Text] [Related]
17. Potent cytotoxic C-11 modified geldanamycin analogues. Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528 [TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG). Chandran T; Katragadda U; Teng Q; Tan C Int J Pharm; 2010 Jun; 392(1-2):170-7. PubMed ID: 20363305 [TBL] [Abstract][Full Text] [Related]
19. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973 [TBL] [Abstract][Full Text] [Related]
20. Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo. Wang X; Yang R; Yuan C; An Y; Tang Q; Chen D Target Oncol; 2018 Aug; 13(4):481-494. PubMed ID: 29992403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]